The Next Generation Bioprinting Market Size is valued projected to record a 29.82 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The next-generation bioprinting industry is being driven by a convergence of factors that represent both technological developments and rising demand for innovative healthcare and biotech solutions.
- The increasing incidence of chronic diseases, rising R&D investment, and technological advancement are other vitally impacting attributes, likely to boost the market growth.
- Asia Pacific dominated the market and accounted for a largest revenue share of global revenue in 2023.
- One of the significant concerns restraining industry growth is the high research and development costs associated with bioprinting technology.
Next generation bioprinting also referred as 4D bioprinting, means adding a fourth dimension to these structures so that they can change their shape over time. The fourth dimension of bioprinting technology is made possible by the use of "smart materials," which change when they are exposed to certain stimuli (such as, heat, water, light, electricity, magnetic energy, stress, strain, and pressure). Structures made with next-generation bioprinting can change shape, but they can also fix themselves and adapt to changes in their environment.
This also includes printing the materials that respond to stimuli and making them work better with bio-inks. Deformed structures made with 4D printing are also hard to put together and fold. 4D bioprinting is getting a lot of attention from both academics and businesspeople. In fact, the amount of related scientific literature has grown by about 130% in the last five years, which shows how popular 4D bioprinting is becoming.
The biomedical industry has greatly benefited from the development of 4D bioprinting or next generation bioprinting technology, particularly in the areas of dentistry, scaffolds, and tissue engineering (TE). This stimulates the market and aids in its expansion overall. Any organ or tissue regeneration that occurs accidentally needs to be replaced. In the end, these factors encourage scientists to consider developing artificial tissues and organs that utilise living cells.
These circumstances will drive the market with research and advancements in bioprinting technology, which is based on bioprinters that can replicate stem cells and organs exactly. Additionally, the market share will increase in the upcoming years due to an increase in start-ups, the expanding use of 4D bioprinting for applications including tissue engineering, regenerative medicine, and medicinal applications, as well as an increase in stakeholder interest in technical breakthroughs.
However, expensive development costs, stringent regulatory restrictions for implantable devices and smart materials used in the product, as well as low awareness in low- and middle-income nations, are some of the reasons impeding market growth.
Competitive Landscape:
Some of The Key Players in The Next Generation Bioprinting Market:
- DirectSync Surgical
- Poietis
- Regenhu
- 3D Systems, Inc.
- GeSiM
- Stratasys
- ROKIT Healthcare
- Sculpteo
- Smart3D
- VIVAX BIO
- EnvisionTec
- EOS GmbH Electro Optical System
- Materialise NV
- Dassault Systèmes
- Organovo Holdings, Inc.
- CellLink
- Izumi International, Inc
- Advanced Solutions Life Sciences. LLC.
Market Segmentation:
The next generation bioprinting market is segmented into three main categories Type of Technology, Application Area and End-User. By the type of technology, it comprises Extrusion-based Technology, Laser-based Technology, Inkjet-based Technology and Others. The application area includes Biomedical Applications and Others. The third segment End-User has Pharmaceutical and Biotechnology Companies, Academic Research and Development and Other End-users.
The Asia Pacific region will probably dominate the global next generation bioprinting market. Asia Pacific's primary dominant factors are new innovations and research, cooperation for development, and big investments in the region.
Recent Developments:
- In February 2023, 3D Systems launched its Regenerative Tissue Program with the goal of offering a superior remedy for reconstructive surgery treatments. This program was started by 3D Systems because of the noteworthy advancements made in the creation of next-generation bioprinting techniques for 3D-printed solid organs. The company is creating vascularized, patient-specific living human tissues by combining bioprinting technology, biocompatible 3D printing materials, and patient-derived cells.
- In Oct 2022, Poietis initiated a three-year partnership to create a clinical-grade cardiac patch with functionalized properties using Poietis' bioprinting technology. The objective of this partnership was to establish the animal model and assess the effectiveness of a bioprinted biomaterial on an in vivo heart failure model. The objective was to reach the stage of clinical trials within a timeframe of three to four years, subsequent to an initial phase of demonstrating the feasibility of the concept.
The Next Generation Bioprinting Market Report Scope:
Report Attribute |
Specifications |
Growth Rate CAGR |
CAGR of 29.82 % from 2024 to 2031 |
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2024 to 2031 |
Historic Year |
2019 to 2023 |
Forecast Year |
2024-2031 |
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
Segments Covered |
By Type of Technology, By Application, By End-User |
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
Competitive Landscape |
DirectSync Surgical, Poietis, 3D Systems, Inc., GeSiM, Regenhu, ROKIT Healthcare, Sculpteo, Smart3D, Stratasys, VIVAX BIO, EnvisionTec, EOS GmbH Electro Optical System, Materialise NV, Dassault Systèmes, Organovo Holdings, Inc., CellLink, Izumi International, Inc, Advanced Solutions Life Sciences. LLC and other market players. |
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |